Hernia Repair Mesh Plcl Absorbable Hernia Articles & Analysis
19 news found
Caresyntax, the leading vendor of enterprise-scale data-driven surgical intelligence solutions to make surgery safer and smarter, today announced its highlights and achievements of 2023, as the company has continued its strong growth journey. Dennis Kogan, co-founder, and CEO: “Caresyntax celebrated its 10-year anniversary in 2023 and accelerated our journey of innovation and expansion ...
CMR Surgical & Surgical Innovations develop new surgical hybrid port access system Surgical Innovations’ new YelloPort Elite™ 5mm, with reusable trocar and canula, reduces cost and waste generated when compared with traditional fully single use Port Access Systems Developed with CMR Surgical, the port access system is the latest addition to Surgical Innovation’s ...
TISSIUM, a privately-owned medtech company developing biomorphic programmable polymers for tissue reconstruction, announced today it has been nominated in the French Tech 120 of the 2022 program. French Tech 120 is a growth-stage program by La FrenchTech, built to provide government-backed support for the 120 fastest growing companies in France. This is the third year in a row that ...
ByTISSIUM
TISSIUM, a privately-owned medtech company developing biomorphic programmable polymers for tissue reconstruction, announced today it has appointed Ruth Krestin as Vice President of Portfolio Strategy within TISSIUM. In this role, she will be responsible for coordinating TISSIUM’s verticals and driving an efficient portfolio-level strategy. Ms. Krestin joins TISSIUM with extensive ...
ByTISSIUM
Asensus Surgical, Inc. (NYSE American: ASXC), a medical device company that is digitizing the interface between the surgeon and the patient to pioneer a new era of Performance-Guided Surgery™, today provided a preliminary 2021 year-end corporate update. Fourth Quarter Highlights Over 500 procedures were performed globally during the quarter, representing growth of over 25% over the ...
Next Science Limited (ASX:NXS) (Next Science) is pleased to announce that it has signed a multi-year distribution agreement with NASDAQ listed medical technology company, TELA Bio, Inc in relation to the supply of a white labelled version of Next Science’s proprietary XPERIENCETM No Rinse Antimicrobial Solution. The new agreement grants TELA Bio, Inc exclusive rights across the US plastic ...
TISSIUM, a privately-owned medtech company developing biomorphic programmable polymers for tissue reconstruction, will present an e-poster on its research on a novel, atraumatic, and consistent hernia mesh fixation device at the Hernia 2021 European Hernia Society – American Hernia Society Joint Congress. The event is scheduled to be held virtually and in-person from October 13 – ...
ByTISSIUM
Imbed Biosciences, Inc. (Imbed), a privately held biotech company emerging as a leader in advanced wound care, announced today the results of a prospective clinical evaluation of its next-generation wound Matrix, Microlyte® SURGICAL, in diabetic patients undergoing foot and ankle surgery who would ordinarily be at risk of a surgical site infection. Results will be published in the October ...
TISSIUM, a privately-owned medtech company developing biomorphic programmable polymers for tissue reconstruction, has announced its research has been selected for presentation within the scientific program at the 76th Annual Meeting of the American Society for Surgery of the Hand. The event is scheduled to be held virtually and in-person from September 30 – October 2, 2021 in San Francisco, ...
ByTISSIUM
TISSIUM, a privately-owned medtech company developing biomorphic programmable polymers for tissue reconstruction, announced it has closed a Series C round of financing, raising €50 million from new and existing international investors. Cathay Health, affiliated to global investment firm Cathay Capital, led new investors and joined other institutional and individual backers while existing ...
ByTISSIUM
Over 400,000 surgeries are conducted every year in the US alone to treat hernias, one of the most common soft tissue injuries. However, the current standard of care is a highly in?ammatory process causing visceral adhesions and postsurgical complications. To address these complications, the team at Baylor College of Medicine recently used our REGENHU bioprinter to design a 3D printed biomesh ...
ByRegenhu
Thanks to those who attended our webinar on Tuesday, January 19th 2021: Reducing Failure Rates in Hiatal and Paraesophageal Hernia Repair – the ‘Achilles Heel’ of Anti-reflux Surgery with Dr. G. Kevin Gillian. A full replay is available here. ...
The Florida Chapter, American College of Surgeons, and Reprise Biomedical are pleased to host a FREE Webinar on Tuesday, January 19th, 2021 at 7:00 p.m. EST. ???? Join us for a 45 min presentation followed by a Q&A session on “Reducing Failure Rates in Hiatal and Paraesophageal Hernia Repair – the ‘Achilles Heel’ of Anti-reflux Surgery” with Dr. G. Kevin Gillian. ...
TISSIUM, a privately-owned medtech company developing biomorphic programmable polymers for tissue reconstruction, announced today it has received approval from the U.S. Food and Drug Administration for its Investigational Device Exemption application for its vascular sealant. The approval is the most recent validation of TISSIUM’s efforts to develop a unique platform of proprietary ...
ByTISSIUM
Continued evolution of EndoGastric Solutions’ EsophyX technology and concomitant use of TIF 2.0 with hiatal hernia repair brings long-term GERD relief to a broader spectrum of patients REDMOND, Wash – June 17, 2020 – EndoGastric Solutions® today announced the publication of a new review article in Therapeutic Advances in Gastroenterology1 that describes the refinement of ...
A 99-patient study confirms that a laparo-endoluminal approach reduces proton pump inhibitor medication use and significantly improves quality-of-life scores REDMOND, Wash – EndoGastric Solutions® today announced the publication of new clinical data confirming that concomitantly performed hiatal hernia (HH) repair and the Transoral Incisionless Fundoplication (TIF® 2.0) procedure ...
Reprise Biomedical, Inc., a Minnesota-based startup focused on commercializing biological medical devices manufactured using a proprietary perfusion decellularization technology, has successfully completed a $12.5 million private placement and commenced operations as a spin-off from Miromatrix Medical Inc. Through the spin-off, Miromatrix transferred to Reprise two existing FDA 510(k) cleared, ...
Colibri Heart Valve LLC, a privately held emerging medical device company focused on structural heart applications, announces the formation of a new company called Colorado Therapeutics LLC. In conjunction with its formation, Colibri has granted Colorado Therapeutics a license to develop and market innovative and disruptive xenogenic (sourced from different mammalian species) biologic tissue ...
Colibri Heart Valve LLC, a privately held emerging medical device company focused on structural heart applications, announces the formation of a new company called Colorado Therapeutics LLC. In conjunction with its formation, Colibri has granted Colorado Therapeutics a license to develop and market innovative and disruptive xenogenic (sourced from different mammalian species) biologic tissue ...